top stories

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

5 hours ago
People
China
AI
Pharma

Stud­ies show how once-ob­scure DNA cir­cles dri­ve can­cer, and maybe even how to stop them

7 hours ago
Discovery

Cal­i­for­nia vot­ers say yes to re­stric­tions around 340B spend­ing

4 hours ago
Pharma
FDA+

CVS names Aet­na head, plans more phar­ma­cy clo­sures as new CEO takes over

7 hours ago
People
Pharma

Latest

Most read

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

9 hours ago
FDA+
In Focus

Macro­Gen­ics paus­es de­vel­op­ment of ADC; Cel­lec­tis de­pri­or­i­tizes CAR-T

8 hours ago
News Briefing

At this year's Obe­si­ty­Week, GLP-1s aren’t the on­ly talk of the town

9 hours ago
R&D

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

11 hours ago
FDA+
Law

No­vo un­veils new car­diometa­bol­ic da­ta as it re­ports sol­id third-quar­ter prof­its

12 hours ago
R&D
Pharma

Aca­dia lands $150M sale of rare pe­di­atric PRV

12 hours ago
Pharma
FDA+
see latest stream
People

Ex­clu­sive: Women’s health uni­corn Maven Clin­ic cuts 10% of its work­force weeks af­ter rais­ing $125M

5 days ago

Elu­ci­da On­col­o­gy, seek­ing foothold in AD­Cs, shut­ters due to 'lack of fund­ing'

Last week

Aper­tu­ra and Ata­lan­ta re­duce head­count en route to­ward the clin­ic

3 weeks ago
Financing

Ex­clu­sive: Blood stem cell ther­a­py mak­er Garu­da gets new CEO, adds $47M

5 days ago

Evom­mune rais­es $115M for I&I pipeline and pre­pares for Phase 2 re­sults

6 days ago

Blue Earth Ther­a­peu­tics snags $76M for both al­pha and be­ta ra­dio­ther­a­pies

Last week
Startups

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

12 hours ago

Cere­bral to pay near­ly $3.7M over con­trolled sub­stance pre­scrib­ing prac­tices

Yesterday

Why hos­pi­tals have been slow to adopt AI for med­ical care

Yesterday
Deals

Prog­nomiQ rais­es $34M for lung can­cer test

Yesterday

Nek­tar di­vests man­u­fac­tur­ing site and reagent arm for $90M 

Yesterday

Eu­ro­pean Com­mis­sion marks Dec. 6 for No­vo-Catal­ent deal de­ci­sion

2 days ago

In FocusSee all

Is there room for MASH drugs in a GLP-1 world?

2 days ago
R&D
Pharma

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Last month
People

Re­cur­sion nears ‘mo­ment of truth’ with first key da­ta, kick­ing off 18-month flur­ry of read­outs

2 months ago
R&D
AI

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

2 months ago
R&D

Endpoints Standouts

How the world's biggest phar­ma and biotech com­pa­nies paid their typ­i­cal work­er in 2023

3 months ago
People
Pharma

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

4 months ago
Financing
Startups

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

4 months ago
People
Special

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

4 months ago
Pharma
Cell/Gene Tx

Peer review See all

Nov
1

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Oct
25

Chi­nook alums re­unite fol­low­ing ex­it to No­var­tis; The first board ap­point­ment for Re­cur­sion’s Chris Gib­son

Oct
18

Ex­clu­sive: Ex-Af­fimed CEO heads to UK nanomed­i­cine biotech; Ja­mi Ru­bin leaves Bound­less Bio af­ter IPO

Oct
11

Lil­ly fol­lows the trend of new AI hires; Pfiz­er fills key UK po­si­tion as ac­tivist hub­bub swells

Oct
4

Af­ter $14B ex­it, Karuna co-founder finds next bet; Ex-Re­genxbio CEO Ken Mills heads to Tag­works

Pharma channel feed

Yesterday

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

SAN AN­TO­NIO — Zealand Phar­ma, hop­ing to cre­ate the next "foun­da­tion­al" ther­a­py for obe­si­ty, de­tailed more Phase 1 da­ta on its amylin ana­log that was the back­bone of a $1 bil­lion raise ...

READ MORE

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Yesterday

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

2 days ago
FDA+
latest in Pharma

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

2 days ago
FDA+

BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

2 days ago

FDA ex­pands faster drug re­view pi­lot from sup­ple­men­tal to full ap­pli­ca­tions

2 days ago
FDA+

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

2 days ago
R&D

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

2 days ago
R&D
see latest stories

Marketing channel feed

4 weeks ago

Val­ne­va and Pfiz­er eye 2027 launch for part­nered Ly­me dis­ease vac­cine

Val­ne­va is eye­ing a 2027 launch for its Pfiz­er-part­nered Ly­me dis­ease vac­cine, CEO Thomas Lin­gel­bach said Thurs­day dur­ing the com­pa­ny’s in­vestor day.

READ MORE

UK watch­dog crit­i­cizes Mod­er­na for Covid-19 tri­al's use of What­sApp to dan­gle pay­ments to chil­dren

Last month
Pharma

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

Last month
Pharma
FDA+
latest in Marketing

Up­dat­ed: Madri­gal fi­nal­ly re­veals first wave of sales for MASH drug Rezd­if­fra

3 months ago
Pharma

RSV mar­ket pres­sure leads to slow­er launch for Mod­er­na's vac­cine

3 months ago
Pharma

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

6 months ago
Financing

From the ed­i­tor: Our fi­nal edi­tion of End­points Mar­ket­ingRx

6 months ago
Editor's note

Mar­ket­ingRx roundup: Mod­er­na de­buts so­cial me­dia sci­ence se­ries; Boehringer ex­pands NY men­tal health ex­hib­it

6 months ago
Pharma
see latest stories

FDA+ channel feed

2 days ago

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

As­traZeneca's Alex­ion, Bridge­Bio, Bio­Marin, Ul­tragenyx and oth­ers, in­clud­ing Sen. Bob Casey (D-PA), re­cent­ly weighed in on the de­tails of a new cross-cut­ting FDA col­lab­o­ra­tion hub fo­cused ...

READ MORE

Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

5 days ago

Fed­er­al court backs FDA's ap­proval of com­peti­tor to Jaz­z's sleep drug

6 days ago
Pharma
Law
latest in FDA+

FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able

Last week

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

Last week
Manufacturing

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Last week
Pharma

Lex­i­con's once-re­ject­ed di­a­betes drug is ques­tioned again by FDA ahead of ad­comm

Last week
Pharma

No­var­tis ex­pands Scem­blix la­bel to first-line CML pa­tients

Last week
Pharma
see latest stories

Manufacturing channel feed

Yesterday

Catal­ent touts cus­tomer con­fi­dence ahead of No­vo deal, but miss­es rev­enue es­ti­mates

Catal­ent re­port­ed a slight rev­enue up­swing dur­ing its lat­est quar­ter­ly re­sults, which CEO Alessan­dro Masel­li at­trib­uted to "cus­tomer­s' con­tin­ued con­fi­dence” in the CD­MO. Yet the ...

READ MORE

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Yesterday
R&D

Bax­ter pulls IV prod­ucts out of Chi­na to shift sup­ply to the US

5 days ago
China
latest in Manufacturing

WuXi in ‘ear­ly stages’ of CGT busi­ness re­view; Lon­za ex­ec be­comes AGC Bio CEO

6 days ago

Mil­li­pore­Sig­ma in­vests €70M to triple ADC man­u­fac­tur­ing at US site 

Last week

WuXi AppTec is still sign­ing on new clients de­spite Biose­cure threat

Last week
China

Telix's new ra­dio­phar­ma spin­out banks on one tri­al for suc­cess, CEO says

Last week
Startups

Post-Hoc: No­vo’s obe­si­ty en­e­mies

Last week
Editor's note
Pharma
see latest stories
A service from the Financial Times